ESTRO 2024 - Abstract Book

S32 ESTRO 2024 reviews, expert consensus, and a pilot study to identify and validate the outcomes. Various validated item libraries were considered for selecting items to cover the identified outcomes and recall periods. Patient involvement was central to our methodology, with patients validating the relevance and comprehensiveness of our outcome set. An item reduction strategy was employed to accommodate the need for frequent outcome assessments, adjusting the outcome set without compromising symptom coverage. Additionally, patient free text reporting was introduced to capture unanticipated adverse events. The need for further adjustments was considered when implementing the outcome set outside the clinical trial. We developed a less time-consuming step-by-step implementation process for clinical practice to develop and validate outcome sets for different patient populations. A systematically developed outcome set presents a robust framework for evaluating acute radiation-induced toxicity. Incorporating patient insights in the development process ensures that the outcome set is also considered relevant by the patients outside clinical trials. Invited Speaker

Implications for future clinical practice:

Developing and implementing PROMs outside clinical trials has the potential to improve the assessment of acute toxicity in radiotherapy, leading to better patient care and treatment outcomes. Its systematic design ensures that it is comprehensive and adaptable for various treatment contexts, making it a valuable tool for clinicians and researchers. However, a less time-consuming but systematic approach must be considered to ensure specific questions are asked and relevant to the selected patient populations.

3326

Diagnostic imaging in prostate cancer - MRI, PSMA PET-CT - Who needs what?

Simon KB Spohn

Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Radiation Oncology, Freiburg, Germany. German Cancer Consortium (DKTK), Partner site DKTK, Freiburg, Germany

Abstract:

PSMA-PET has emerged as a molecular imaging modality for the staging of prostate cancer and plays a significant role in treatment decision-making. PSMA-PET provides complementary information in addition to multiparametric MRI, yet interpreting findings both within and outside the prostate remains challenging, particularly in case of equivocal findings in bones. This presentation will focus on the performance of PSMA-PET and MRI for both local and distant staging, along with their implications for therapy strategies. It will discuss which patients should undergo PSMA-PET to ensure optimal resource management. Moreover, the presentation will highlight the integration of functional imaging into radiotherapy planning and how deeper analysis of images can contribute to personalized treatment approaches.

3327

Dose and fractionation: Does one size fits all?

Andrew Loblaw